-
-
-
-
-
-
-
Larimar Therapeutics, Inc. (LRMR) Misses Q4 EPS by 14c
-
-
-
-
-
-
-
Larimar Therapeutics, Inc. (LRMR) Misses Q1 EPS by 3c
-
-
-
-
-
-
-
Larimar Therapeutics (LRMR) Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels
-
-
-
-
-
-
-
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
-
-
-
-
-
-
-
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

